Biocon Biologics and Viatris launch first-ever interchangeable biosimilars SEMGLEE and Insulin Glargine injection in US, Health News, ET HealthWorld

Bengaluru : Biocon Biologics Ltd, a subsidiary of Biocon and Viatris Inc, announced the US launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

In a statement Biocon Biologics Ltd informed that both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS® (insulin glargine), allowing for substitution at the pharmacy counter.

Commenting on the launch of both biosimilar products in US, Shreehas Tambe, Deputy CEO, Biocon Biologics said, “The launch of our interchangeable biosimilar insulin glargine in the U.S. by our partner Viatris, is in line with our aspiration to provide our biosimilar insulins to ‘one in five’ insulin dependent people with diabetes, globally. This is indeed a landmark event and along with the recent formulary listings, we believe it will allow us to improve accessibility, availability and adoption of biosimilars in the U.S. for the benefit of patients and the overall healthcare system.”

SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris and Biocon Biologics, are

View More Biocon Biologics and Viatris launch first-ever interchangeable biosimilars SEMGLEE and Insulin Glargine injection in US, Health News, ET HealthWorld